- Home
- GIX vs PRTA Comparison
GIX vs PRTA Comparison
Compare GIX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GIX | PRTA |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.4M | 429.2M |
| IPO Year | 2025 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GIX | PRTA |
|---|---|---|
| Price | $10.03 | $8.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.40 |
| AVG Volume (30 Days) | 37.4K | ★ 461.6K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $775.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.80 | $7.73 |
| 52 Week High | $10.04 | $11.80 |
Technical Indicators
Market Signals| Indicator | GIX | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 51.84 |
| Support Level | $9.92 | $8.06 |
| Resistance Level | $10.04 | $9.25 |
| Average True Range (ATR) | 0.00 | 0.45 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 75.00 | 54.29 |
Price Performance
Historical ComparisonAbout GIX GigCapital9 Corp. Class A Ordinary Share
GigCapital9 Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.